Allspring Global Investments Holdings LLC Invests $335,000 in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Allspring Global Investments Holdings LLC acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,892 shares of the medical equipment provider’s stock, valued at approximately $335,000.

A number of other hedge funds have also added to or reduced their stakes in SNN. Hara Capital LLC increased its stake in Smith & Nephew SNATS by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 1,957 shares during the last quarter. US Bancorp DE increased its stake in Smith & Nephew SNATS by 21.8% in the fourth quarter. US Bancorp DE now owns 13,604 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 2,437 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Smith & Nephew SNATS by 18.2% in the fourth quarter. Jones Financial Companies Lllp now owns 11,696 shares of the medical equipment provider’s stock valued at $287,000 after acquiring an additional 1,797 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Smith & Nephew SNATS by 22.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,305 shares of the medical equipment provider’s stock valued at $819,000 after acquiring an additional 6,106 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Smith & Nephew SNATS in the fourth quarter valued at approximately $4,992,000. 25.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their target price on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a “hold” rating in a research report on Thursday, May 1st. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Finally, HSBC lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.00.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $31.05 on Friday. The firm has a market cap of $13.60 billion, a PE ratio of 14.37, a price-to-earnings-growth ratio of 0.94 and a beta of 0.69. The firm’s fifty day moving average is $29.30 and its 200-day moving average is $27.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.33 and a current ratio of 2.89. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $31.72.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.